HN2008001859A - Sales de n-hodroxi-3-{4-{{{2-(2-metil-1h-indol-3-il)etil}metil}fenil}-2e--2-propenamida. - Google Patents

Sales de n-hodroxi-3-{4-{{{2-(2-metil-1h-indol-3-il)etil}metil}fenil}-2e--2-propenamida.

Info

Publication number
HN2008001859A
HN2008001859A HN2008001859A HN2008001859A HN2008001859A HN 2008001859 A HN2008001859 A HN 2008001859A HN 2008001859 A HN2008001859 A HN 2008001859A HN 2008001859 A HN2008001859 A HN 2008001859A HN 2008001859 A HN2008001859 A HN 2008001859A
Authority
HN
Honduras
Prior art keywords
methyl
indol
phenyl
salts
hodroxi
Prior art date
Application number
HN2008001859A
Other languages
English (en)
Inventor
Murat Acemoglu
Joginder Bajwa
Piotr Karpinski
Dimitris Papoutsakis
Joel Slade
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2008001859(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HN2008001859A publication Critical patent/HN2008001859A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE PREPARAN Y SE CARACTERIZAN SALES DE N-HIDROXI-3-{4-{{{2-(2-METIL)-1H-INDOL-3-IL)ETIL}AMINO}METIL}FENIL}-2E-2-PROPENAMIDA.
HN2008001859A 2006-06-12 2008-12-11 Sales de n-hodroxi-3-{4-{{{2-(2-metil-1h-indol-3-il)etil}metil}fenil}-2e--2-propenamida. HN2008001859A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452306P 2006-06-12 2006-06-12
US86999306P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
HN2008001859A true HN2008001859A (es) 2011-07-19

Family

ID=38564366

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2008001859A HN2008001859A (es) 2006-06-12 2008-12-11 Sales de n-hodroxi-3-{4-{{{2-(2-metil-1h-indol-3-il)etil}metil}fenil}-2e--2-propenamida.

Country Status (38)

Country Link
US (3) US20090197936A1 (es)
EP (1) EP2032531B1 (es)
JP (2) JP2009540005A (es)
KR (2) KR20090026281A (es)
AR (1) AR061298A1 (es)
AU (1) AU2007257962B2 (es)
BR (1) BRPI0712771A2 (es)
CA (1) CA2654439C (es)
CL (1) CL2007001692A1 (es)
CR (1) CR10439A (es)
DK (1) DK2032531T3 (es)
EA (1) EA015212B1 (es)
EC (1) ECSP088979A (es)
ES (1) ES2570934T3 (es)
GE (1) GEP20105125B (es)
GT (1) GT200800279A (es)
HK (1) HK1126496A1 (es)
HN (1) HN2008001859A (es)
HR (1) HRP20160291T1 (es)
HU (1) HUE027126T2 (es)
IL (1) IL195087A (es)
JO (1) JO3138B1 (es)
MA (1) MA30563B1 (es)
ME (1) ME00531B (es)
MX (1) MX2008015901A (es)
MY (1) MY147345A (es)
NO (1) NO341871B1 (es)
NZ (1) NZ572547A (es)
PE (1) PE20080937A1 (es)
PL (1) PL2032531T3 (es)
RS (1) RS54640B1 (es)
SI (1) SI2032531T1 (es)
SM (1) SMP200900002B (es)
SV (1) SV2008003126A (es)
TN (1) TNSN08501A1 (es)
TW (1) TWI409254B (es)
UY (1) UY30403A1 (es)
WO (1) WO2007146715A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0712993A2 (pt) 2006-06-12 2012-04-17 Novartis Ag polimorfos de n-hidróxi-3-[4[[[2-(2-metil-1h-indol-3-il) etil]amino]metil]fenil]-2e-2-propenamida
MX2009007343A (es) * 2007-01-10 2009-07-15 Novartis Ag Formulaciones de inhibidores de desacetilasa.
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
JP5263211B2 (ja) 2010-03-30 2013-08-14 ブラザー工業株式会社 サーバ、プリンタ、及び、サーバのためのコンピュータプログラム
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
MA41544A (fr) 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
WO2017221163A1 (en) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Novel salts and polymorphic forms of panobinostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2005013958A1 (en) * 2003-08-07 2005-02-17 Novartis Ag Histone deacetylase inhibitors as immunosuppressants
US20050228300A1 (en) * 2004-04-07 2005-10-13 Triage Data Networks Cuffless blood-pressure monitor and accompanying wireless mobile device
JP2009540007A (ja) * 2006-06-12 2009-11-19 ノバルティス アクチエンゲゼルシャフト Ｎ−ヒドロキシ−３−［４−［［［２−（２−メチル−１ｈ−インドール−３−イル）エチル］アミノ］メチル］フェニル］−２ｅ−２−プロペンアミドの塩の製造方法
BRPI0712993A2 (pt) * 2006-06-12 2012-04-17 Novartis Ag polimorfos de n-hidróxi-3-[4[[[2-(2-metil-1h-indol-3-il) etil]amino]metil]fenil]-2e-2-propenamida

Also Published As

Publication number Publication date
KR101629352B1 (ko) 2016-06-13
KR20090026281A (ko) 2009-03-12
TWI409254B (zh) 2013-09-21
AU2007257962A1 (en) 2007-12-21
WO2007146715A1 (en) 2007-12-21
RS54640B1 (en) 2016-08-31
HK1126496A1 (zh) 2009-09-04
UY30403A1 (es) 2008-01-31
IL195087A (en) 2012-10-31
AU2007257962B2 (en) 2011-06-23
CA2654439A1 (en) 2007-12-21
EA200802382A1 (ru) 2009-06-30
SI2032531T1 (sl) 2016-05-31
NO20090128L (no) 2009-03-11
IL195087A0 (en) 2009-08-03
JP2013256542A (ja) 2013-12-26
NO341871B1 (no) 2018-02-12
MX2008015901A (es) 2009-01-12
JO3138B1 (ar) 2017-09-20
HUE027126T2 (en) 2016-08-29
TNSN08501A1 (en) 2010-04-14
KR20150029765A (ko) 2015-03-18
EP2032531B1 (en) 2016-02-10
BRPI0712771A2 (pt) 2012-09-25
US20090197936A1 (en) 2009-08-06
JP5771257B2 (ja) 2015-08-26
TW200815343A (en) 2008-04-01
EP2032531A1 (en) 2009-03-11
EA015212B1 (ru) 2011-06-30
CR10439A (es) 2009-01-15
NZ572547A (en) 2011-06-30
DK2032531T3 (en) 2016-04-11
CL2007001692A1 (es) 2008-05-09
US20110112308A1 (en) 2011-05-12
JP2009540005A (ja) 2009-11-19
PE20080937A1 (es) 2008-08-29
ECSP088979A (es) 2009-01-30
PL2032531T3 (pl) 2016-07-29
ME00531B (me) 2011-10-10
MY147345A (en) 2012-11-30
GT200800279A (es) 2010-06-16
GEP20105125B (en) 2010-11-25
AR061298A1 (es) 2008-08-20
CA2654439C (en) 2014-08-05
MA30563B1 (fr) 2009-07-01
HRP20160291T1 (hr) 2016-04-22
US20100286409A1 (en) 2010-11-11
ES2570934T3 (es) 2016-05-23
SMAP200900002A (it) 2009-01-14
SV2008003126A (es) 2011-07-05
SMP200900002B (it) 2010-01-19

Similar Documents

Publication Publication Date Title
HN2008001859A (es) Sales de n-hodroxi-3-{4-{{{2-(2-metil-1h-indol-3-il)etil}metil}fenil}-2e--2-propenamida.
GT200800280A (es) Polimorfo de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida
DK1989206T3 (da) E1-aktiveringsenzymhæmmere
DK1912636T3 (da) N-(arylamino)-sulfonamid-inhibitorer af mek
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
BRPI0814719A2 (pt) N-(2-(hetaril)aril)arilsulfonamidas e n-(2-(hetaril)arilsulfonamidas
CY2014011I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
RS53770B1 (en) CRYSTAL FORM OF INHIBITOR FOR MDM2 / 4 AND P53 INTERACTIONS
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
DK2848610T3 (da) Hæmmere af kinaseaktivitet
ATE552262T1 (de) Spiroketone als inhibitoren von acetyl-coa- carboxylase
NO20076678L (no) Glutamataggrekanaseinhibitorer
DE602005019971D1 (de) Inhibitoren von cysteinprotease
GT201200280A (es) Procedimiento
DK2091945T3 (da) Nye inhibitorer af glutaminylcyclase
EA200800065A1 (ru) Аминокислые соли росиглитазона
BRPI0921596A2 (pt) Compostos de 4-[2-(2-fluorofenoximetil) fenil] piperidina
DK2035432T3 (da) 2-(substitueret amino)-benzothiazolsulfonamid-HIV-proteaseinhibitorer
NO20082185L (no) Heterocykliske CETP-inhibitorer
FI20075264A0 (fi) Heterosykliset fenyylikarbamaatit uusina FAAH-inhibiittoreina
DK1904490T3 (da) Ethanolaminsalt af N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridin-3-sulfonamid
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.
CU20080237A7 (es) Polimorfos de n-hidroxi-3-[4-[[[2-metil-1h-indol-3-il)etil]amino]metil]fenil]2e-2-propenamida